A5026802539- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Breast Implant and Reconstruction
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Acute Myeloid Leukemia Research
- Lung Cancer Research Studies
- Ethics in Clinical Research
- Cancer Research and Treatments
- Advanced Radiotherapy Techniques
- Polysaccharides and Plant Cell Walls
- Economic and Financial Impacts of Cancer
- Hemoglobinopathies and Related Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Medication Adherence and Compliance
- HER2/EGFR in Cancer Research
- Palliative Care and End-of-Life Issues
Methodist Hospital
2021-2025
Houston Methodist
2021-2024
Advanced Centre for Treatment, Research and Education in Cancer
2024
Tata Memorial Hospital
2024
The University of Texas MD Anderson Cancer Center
2023
American Society of Clinical Oncology
2022
University of Louisville
2010-2021
Norton Healthcare
2018-2020
James Graham Brown Foundation
2009-2014
Mercy Medical Center
2003
PURPOSE The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations. A update NSCLC alterations will be published separately. METHODS American Society Clinical Oncology and Ontario Health (Cancer Care Ontario) Expert Panel made updated based a systematic review randomized controlled trials from December 2015 2019. RESULTS This reflects changes in...
PURPOSE To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) driver alterations. A update NSCLC without alterations was published separately. METHODS The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) Expert Panel updated based a systematic review randomized controlled trials (RCTs) from December 2015 to January 2020 meeting abstracts 2020. RESULTS This...
To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer without driver alterations.ASCO updated basis of an ongoing systematic review randomized clinical trials from 2018 to 2021.This update reflects changes in evidence since previous update. Five base. Outcomes interest include efficacy safety.In addition options high programmed death ligand-1 (PD-L1)...
Living guidelines are routinely updated that developed for selected topic areas with rapidly evolving evidence drives frequent change in clinical practice. These on a regular schedule, based the work of standing panel reviews literature continuous basis. Updates will be made regularly and can found at https://ascopubs.org/nsclc-da-living-guideline . PURPOSE To provide evidence-based recommendations updating 2021 ASCO Ontario Health (Cancer Care Ontario) guideline systemic therapy patients...
ASCO Rapid Recommendation Updates highlight revisions to select guideline recommendations as a response the emergence of new and practice-changing data. The rapid updates are supported by an evidence review follow development processes outlined in Guideline Methodology Manual. goal these articles is disseminate updated recommendations, timely manner, better inform health practitioners public on best available cancer care options. Guidelines not intended substitute for independent...
Abstract Tumor-associated macrophages (TAM) with an alternatively activated phenotype have been linked to tumor-elicited inflammation, immunosuppression, and resistance chemotherapies in cancer, thus representing attractive target for effective cancer immunotherapy. In this study, we demonstrate that particulate yeast-derived β-glucan, a natural polysaccharide compound, converts polarized or immunosuppressive TAM into classically potent immunostimulating activity. This process is associated...
First-line surgical options for early-stage breast cancer include breast-conserving surgery (BCS) or mastectomy. We analyzed factors that influence the receipt of mastectomy and resultant trends over time.We rates BCS 1634 women who underwent upfront treatment AJCC stage 0, I, II between 1995 2008 using data from University Louisville James Graham Brown Cancer Center Tumor Registry. examined trend time assessed probability receiving multivariate logistic regression.Overall, 65.9% received...
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis; as described theASCO Guidelines Methodology Manual. ASCO follow Conflict of Interest Policy Implementation Clinical Practice Guidelines. and updates not intended to substitute independent professional judgment treating provider do account...
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual. follow Conflict of Interest Policy Implementation Clinical Practice Guidelines. and updates not intended to substitute independent professional judgment treating provider do...
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described theASCO Guidelines Methodology Manual. ASCO follow Conflict of Interest Policy Implementation Clinical Practice Guidelines. and updates not intended to substitute independent professional judgment treating provider...
The 21-gene assay recurrence score (RS) can guide the use of chemotherapy for management patients with pN0- 1 [1-3 positive lymph nodes (LNs)] breast cancer. However, practice patterns based on this assay, as well associated outcomes, have not been evaluated pN2 (4-9 LNs) disease. National Cancer Database (NCDB) was queried newly-diagnosed, non-metastatic, hormone receptor-positive, Her2-negative, cancer who underwent adjuvant endocrine therapy and had a known RS. Kaplan-Meier analysis used...
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual. follow Conflict of Interest Policy Implementation Clinical Practice Guidelines. and updates not intended to substitute independent professional judgment treating provider do...
Purpose: To examine the impact of radiotherapy on breast cancer patients with triple-negative (ER-, PR-, HER2/neu-) disease. Materials and Methods: A prospectively collected database 152 triple negative was initiated in 2004. total 77 who had all phases their therapy (surgery, chemotherapy, radiotherapy) at our institution a minimum 2-months follow-up are included. Patients types surgery (lumpectomy or mastectomy), chemotherapy (neoadjuvant adjuvant), (tangents only comprehensive nodal...
To analyze factors that influence the timing of adjuvant chemotherapy in patients who are candidates for breast-conservation therapy (BCT) but elect mastectomy with immediate reconstruction (M-IR).We identified 35 consecutively treated stage I or II breast cancer between 2004 and 2009 underwent M-IR from University Louisville Cancer Registry. We matched these age AJCC to controls BCT chemotherapy. examined delay initiation using univariate logistic regression McNemar test pairs.For 70...
Abstract Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a very common dose-limiting side effect of many cancer treatments. However, the optimal treatment for CIPN remains unclear. Electroacupuncture (EA) non-pharmacologic that combines traditional acupuncture with electrical stimulation. EA being examined and has shown modest benefits. Design: This pilot, single-center, prospective, single-arm, non-blinded study. All subjects had residual grade ≥2 after having received...